The Future of Weight Management

Retatrutide (LY3437943) is an investigational triple agonist medication developed by Eli Lilly. It simultaneously activates GLP-1, GIP, and glucagon receptors — three key metabolic pathways — making it the first triple-receptor agonist in clinical development for obesity and metabolic health.

Semaglutide targets only the GLP-1 receptor, while tirzepatide acts on both GLP-1 and GIP receptors. Retatrutide is unique as a triple agonist, additionally activating the glucagon receptor. The glucagon component may enhance energy expenditure and fat metabolism, potentially leading to greater weight loss outcomes.

The Phase 2 trial, published in the New England Journal of Medicine in June 2023, reported that participants receiving the highest dose of retatrutide achieved up to approximately 24% mean body weight loss at 48 weeks. Phase 3 trials are currently underway to confirm these results in larger populations.

No. As of 2026, retatrutide is still investigational and has not been approved by the FDA or any other regulatory agency. It can only be accessed through legitimate clinical trials. Discuss FDA-approved weight management options with a licensed healthcare provider.

In clinical trials, the most common side effects were gastrointestinal in nature, including nausea, diarrhea, vomiting, and decreased appetite — consistent with the GLP-1 drug class. These symptoms were generally mild to moderate and often decreased with gradual dose titration.

Eli Lilly is conducting Phase 3 clinical trials. If successful, the company would submit for regulatory approval, which typically takes additional time for review. No specific timeline for commercial availability has been announced. Check our articles for the latest updates on trial progress.